Prediction of Immune-Checkpoint Blockade Monotherapy Response in Patients With Melanoma Based on Easily Accessible Clinical Indicators

BACKGROUND: Immune checkpoint blocker (ICB) has shown significant clinical activity in melanoma. However, there are no clinically approved biomarkers to aid patient selection. We aimed to identify patients with advanced or metastatic melanoma who are likely to benefit from ICB monotherapy using easi...

Descripción completa

Detalles Bibliográficos
Autores principales: Byun, Hwa Kyung, Chang, Jee Suk, Jung, Minkyu, Koom, Woong Sub, Chung, Kee Yang, Oh, Byung Ho, Roh, Mi Ryung, Kim, Kyung Hwan, Lee, Choong-Kun, Shin, Sang Joon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8190329/
https://www.ncbi.nlm.nih.gov/pubmed/34123816
http://dx.doi.org/10.3389/fonc.2021.659754

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8190329/
https://www.ncbi.nlm.nih.gov/pubmed/34123816
http://dx.doi.org/10.3389/fonc.2021.659754

Ejemplares similares